A high proportion of founder BRCA1 mutations in Polish breast cancer families. - Test2 - elhamkhani - TriplyDB

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

http://www.wikidata.org/entity/Q34548008

about

Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations A common missense variant in BRCA2 predisposes to early onset breast cancer.New challenges for BRCA testing: a view from the diagnostic laboratory BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk.Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism.High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series.BRCA1 4153delA founder mutation in Russian ovarian cancer patients Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers BRCA1 founder mutations compared to ovarian cancer in Belarus.Population screening for hereditary and familial cancer syndromes in Valka district of Latvia Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization.Common low-penetrance risk variants associated with breast cancer in Polish women.Breast cancer prevention in women with a BRCA1 or BRCA2 mutation.Triple-negative breast cancers: an updated review on treatment options Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing.New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers Cumulative Small Effect Genetic Markers and the Risk of Colorectal Cancer in Poland, Estonia, Lithuania, and Latvia.The risk of breast cancer in women with a BRCA1 mutation from North America and Poland.Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.Unique Features of Germline Variation in Five Egyptian Familial Breast Cancer Families Revealed by Exome Sequencing.BRCA1 founder mutations do not contribute to increased risk of gastric cancer in the Polish population.Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland Breast cancer susceptibility testing: past, present and future.Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status Prevalence of the BRCA1 c.68_69delAG (BIC: 185delAG) mutation in women with breast cancer from north-central Poland and a review of the literature on other regions of the country.Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer Comparison of whole genome amplification and nested-PCR methods for preimplantation genetic diagnosis for BRCA1 gene mutation on unfertilized oocytes-a pilot study.PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers.BRCA1 testing.Selected aspects of genetic counselling for BRCA1 mutation carriers.

P2860

Q24675652-D9A5B5DE-C0D6-4B61-BB7C-1E534BB0A717 Q24813558-E9532EDF-3FFD-4152-B56B-609054B4177C Q25257213-A4FA1B0D-80F6-428A-9F94-0A9BBB7930A1 Q25257499-87801FCF-2A91-46EF-8442-94DDF33DA768 Q26741855-C0E19101-4429-491F-92E6-4FF463F64541 Q27002334-19E1ACFE-3D22-4CC5-83E6-BBC278CAB14C Q33289259-2C0A31BA-1CDA-47FA-9FEA-47E9584282FD Q33327308-F2C44734-E2BA-4B79-968A-C2C24E1C3C67 Q33687533-BB04BFBE-822F-4319-BBBF-6BA3DEAA5A9A Q33722598-92610EA0-CA1D-4F3A-ACAB-0D9A45B5403E Q33732336-86AD8A64-C434-42CE-ADD6-F60DD3AECAB2 Q33823472-84585A14-47AF-47B8-AFCF-A68424BE7750 Q34185187-FFCBDFF4-EEB5-4588-B5BE-CE5229C873D3 Q34297189-8F428592-03D0-4E70-8088-3606E298A7C0 Q34367165-CCBE4952-D101-460F-9A5B-51515FC88B04 Q34493797-D52D6197-A5B3-44CB-B004-0A5839AB3946 Q35039870-F468E0BE-24FB-4148-8514-2082B4F07EFB Q35145678-52EB9391-7BE5-40DF-9EB7-E77DAE9EA56A Q35546258-F21F6CDA-D857-418B-8F80-02BD1B9D2E31 Q35600785-BE019F01-2312-43FB-A285-25CF311C922A Q35645650-5027D84F-A332-460A-BC9E-516CE3F2F92D Q35665705-7B074A7F-529C-41CE-9CF5-64D4A18CC98A Q35697872-1CD8305A-339A-408B-B9AD-4868024D85DC Q35907001-1F1DDF10-7E74-421E-BD6A-F9E0DABD8972 Q36108160-F7AC94F2-FEEE-4773-AE22-D2B1D7B75856 Q36117690-426D739A-60C1-4749-8281-37963E4700E7 Q36246433-E32BD9E5-AE9B-4B17-83A8-F08C10828618 Q36466697-AF0D84C5-4DE5-47D9-8BA5-928B9C73E97C Q36538025-05E86817-8C22-4F17-91C5-49AC41BFEDC1 Q36573827-1B92DD4E-E08B-4E23-81F7-E28A81E3F2A8 Q36642880-54B887A9-3BB2-44A2-817E-5346D89E5D28 Q36924418-6CC978D5-0067-4A00-8C1E-B0C9BF718AF6 Q36930042-2C89E528-54E4-4E46-8FD9-786808873893 Q36936755-9704661A-D4A6-48D1-987D-F83B88C151D5 Q36962696-8858110F-16FE-4343-BACE-2B88B1D42803 Q37004792-3C1992A9-171E-471E-A369-34847593E50D Q37116781-12E58747-F203-42E5-BF68-F2E99F4EF857 Q37316953-C1C39E82-F251-4D15-92EB-8A4A107EAF01 Q37327095-AFCE4DBF-B557-40D9-8760-943DB82AA81D Q37330009-BC623D36-C4EF-4292-ACD3-20676CF795F7

P2860

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

http://www.wikidata.org/entity/Q34548008

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@ast

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@en

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@nl

type

label

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@ast

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@en

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@nl

prefLabel

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@ast

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@en

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@nl

P1433

Q34548008-0A3881B4-5B9F-4218-85C7-5FCB53C20183

P1476

Q34548008-6BD34EEC-9825-4C3E-A3C5-9FD353E44872

P2093

Q34548008-01D14EC8-9294-4F4D-8A42-55FFB660DEEA

Q34548008-08DC7B00-D8F1-464D-B2DE-0FACEC9A16E9

Q34548008-107E332F-756B-45DC-B316-A2404EB60AAB

Q34548008-126B08A9-2960-438B-AC2A-70F4568CE402

Q34548008-17D7FB59-102F-4D4D-827B-0413BA397098

Q34548008-18CD7608-F2EB-4C26-A242-BB1BCDE5DE58

Q34548008-21321845-8636-4D41-A0AC-2AE6A1409338

Q34548008-2B43A5A8-B53A-4843-BB07-BB4937270965

Q34548008-35EB3D0C-4805-4D73-9D80-69D5E054C24A

Q34548008-3F7BC39B-4F5B-46D5-95AB-A54BDF1C05F9

P2860

Q34548008-0673913D-A13A-45F4-AD44-199FD551AEF4

Q34548008-10DC80D6-D62A-40D2-B160-BE3F058E01D7

Q34548008-15AD411B-24EB-4FE2-B262-D131E8ADB174

Q34548008-4E913C12-F816-415A-856C-C8AEF5FAECB4

Q34548008-57413DB1-CCCD-485A-AD34-7BD20F2BF65F

Q34548008-88789B37-B16C-4C4B-8C73-8029A6514FAA

Q34548008-88D9344E-CAAE-41D3-9B70-0A1BCD612DCA

Q34548008-8D5C3F79-81F5-4729-861D-CCC40FD05840

Q34548008-C16BF6E5-FC4E-4D75-8DB8-B1BB46AFFBB7

Q34548008-CB7B803B-29BE-405E-A7B4-31CB1212DD90

P304

Q34548008-2C1632EF-8E6C-4520-953B-9AD95183EC87

P31

Q34548008-EAA18AE4-F20A-4CAC-80D1-D63EA66F07F3

P356

Q34548008-B72451B7-C10B-44A0-8318-0536BAA64995

P433

Q34548008-9B662EA0-2F6F-46B7-9205-67DA0E09C996

P478

Q34548008-A3808895-DF00-4F63-AE50-7A06FED3DD49

P50

Q34548008-258AC0AB-EDEB-468D-9DE8-D7BF8F675118

Q34548008-3345E61E-27C0-4B1F-A5A3-106B3FA0F566

Q34548008-589D6788-3158-438C-B40D-8773DBC16D68

Q34548008-89623DD4-0C4C-4276-8EBF-177EFA859D34

Q34548008-F5F05651-14FC-401A-89F8-D7A40331C54C

Q34548008-FB13A4D8-5F1F-4F3A-A591-DC37DD528DDD

P577

Q34548008-C4D524A7-1E49-4953-8838-F2D483A83F0F

P5875

Q34548008-13766747-80FA-4CEB-BACD-1ECD9D09E557

P698

Q34548008-70B95A5C-0789-4436-9E41-6D52B298415B

P356

P1433

International Journal of Cancer

P1476

A high proportion of founder BRCA1 mutations in Polish breast cancer families.

@en

P2093

Aleksandra Tołoczko-Grabarek

http://www.w3.org/2001/XMLSchema#string

Andrzej Mackiewicz

http://www.w3.org/2001/XMLSchema#string

Andrzej Rozmiarek

http://www.w3.org/2001/XMLSchema#string

Bartłomiej Masojć

http://www.w3.org/2001/XMLSchema#string

Bernard Waśko

http://www.w3.org/2001/XMLSchema#string

Bogusław Debniak

http://www.w3.org/2001/XMLSchema#string

Bohdan Górski

http://www.w3.org/2001/XMLSchema#string

Dagmara Sorokin

http://www.w3.org/2001/XMLSchema#string

Dorota Czudowska

http://www.w3.org/2001/XMLSchema#string

Elzbieta Kowalska

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence of founder mutations in Finnish BRCA1 and BRCA2 families

Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland.

Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families.

Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations.

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.

P304

683-686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.20162

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Stanisław Góźdź

Cezary Cybulski

Anna Jakubowska

Janusz Menkiszak

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8558712

http://www.w3.org/2001/XMLSchema#string

P698

15146557

http://www.w3.org/2001/XMLSchema#string